{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:01:44Z","timestamp":1792512104908,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,22]],"date-time":"2016-11-22T00:00:00Z","timestamp":1479772800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2955-0","type":"journal-article","created":{"date-parts":[[2016,11,22]],"date-time":"2016-11-22T12:16:59Z","timestamp":1479817019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study"],"prefix":"10.1186","volume":"16","author":[{"given":"Ajai","family":"Chari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Mezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winifred","family":"Werther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Felici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Lyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,22]]},"reference":[{"key":"2955_CR1","doi-asserted-by":"crossref","unstructured":"Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, et al. NCCN Guidelines insights: Multiple myeloma, Version 3.2016. J Natl Compr Canc Netw. 2016;14(4):389\u2013400.","DOI":"10.6004\/jnccn.2016.0046"},{"key":"2955_CR2","unstructured":"SEER Cancer Statistics Factsheets. Myeloma. Bethesda: National Cancer Institute. http:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html . Accessed 11 Feb 2016."},{"issue":"1","key":"2955_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.hfc.2011.08.011","volume":"8","author":"JD Strait","year":"2012","unstructured":"Strait JD, Lakatta EG. Aging-associated cardiovascular changes and their relationship to heart failure. Heart Fail Clin. 2012;8(1):143\u201364.","journal-title":"Heart Fail Clin"},{"key":"2955_CR4","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/00005650-200208000-00007","volume":"40","author":"H Quan","year":"2002","unstructured":"Quan H, Parsons GA, Ghali WA. Validity of information on comorbidity derived from ICD-9-CM administrative data. Med Care. 2002;40:675\u201385.","journal-title":"Med Care"},{"issue":"10","key":"2955_CR5","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.ctrv.2015.07.005","volume":"41","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos MA, Terpos E, Niesvizky R, Palumbo A. Clinical characteristics of patients with relapsed multiple myeloma. Cancer Treat Rev. 2015;41(10):827\u201335.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"2955_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142\u201352.","journal-title":"N Engl J Med"},{"key":"2955_CR7","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/cncr.27745","volume":"119","author":"D White","year":"2013","unstructured":"White D, Kassim A, Bhaskar B, Yi J, Wamstad K, Paton VE. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma. Cancer. 2013;119:339\u201347.","journal-title":"Cancer"},{"key":"2955_CR8","doi-asserted-by":"crossref","first-page":"e19563","DOI":"10.1200\/jco.2014.32.15_suppl.e19563","volume":"32","author":"KD Kistler","year":"2014","unstructured":"Kistler KD, Murphy B, Kalman J, Sahni G, Werther W, Rajangam K, et al. A comparison of cardiac event rates in patients with or without multiple myeloma in the United States. J Clin Oncol. 2014;32:e19563.","journal-title":"J Clin Oncol"},{"key":"2955_CR9","volume-title":"Hypertension among adults in the US: National Health and Nutrition Examination Survey, 2011\u20132012. NCHS Data Brief, No. 133","author":"T Nwankwo","year":"2013","unstructured":"Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the US: National Health and Nutrition Examination Survey, 2011\u20132012. NCHS Data Brief, No. 133. Hyattsville: National Center for Health Statistics, Centers for Disease Control and Prevention, US Dept of Health and Human Services; 2013."},{"issue":"22","key":"2955_CR10","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1001\/archinte.167.22.2431","volume":"167","author":"ND Wong","year":"2007","unstructured":"Wong ND, Lopez VA, Italien GL, Chen R, Kline SEJ, Franklin SS. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003\u20132004. Arch Intern Med. 2007;167(22):2431\u201336.","journal-title":"Arch Intern Med"},{"issue":"21","key":"2955_CR11","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1182\/blood.V124.21.1301.1301","volume":"124","author":"YJ Chen","year":"2014","unstructured":"Chen YJ, De AP, Cong Z, Aggarwal SK, Wade RL. Demographic and comorbidity characteristics of newly diagnosed multiple myeloma patients in the United States: A real world data analysis. Blood. 2014;124(21):1301.","journal-title":"Blood"},{"key":"2955_CR12","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1161\/01.HYP.37.4.1053","volume":"37","author":"JR Sowers","year":"2001","unstructured":"Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease. An update. Hypertension. 2001;37:1053\u20139.","journal-title":"Hypertension"},{"issue":"5","key":"2955_CR13","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 Evidence-based guidelines for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC8). JAMA. 2014;311(5):507\u201320.","journal-title":"JAMA"},{"key":"2955_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2169\/internalmedicine.52.8799","volume":"52","author":"G Oshikawa","year":"2013","unstructured":"Oshikawa G, Kojima A, Doki N, Kobayashi T, Kakihana K, Tsuda H, et al. Bortezomib-induced posterior reversible encephalopathy syndrome in a patients with newly diagnosed multiple myeloma. Intern Med. 2013;52:111\u201314.","journal-title":"Intern Med"},{"issue":"2","key":"2955_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s12185-008-0130-3","volume":"88","author":"S Yang","year":"2008","unstructured":"Yang S, Jun M, Hong-Li Z, Jian-Min W, Chun W, Lu-Gui Q, et al. A multi-center open-labeled study of recombinant erythropoietin-beta in the treatment of anemic patients with multiple myeloma, low-grade non-Hodgkin\u2019s lymphoma, or chronic lymphocytic leukemia in Chinese population. Int J Hematol. 2008;88(2):139\u201344.","journal-title":"Int J Hematol"},{"key":"2955_CR16","unstructured":"Zhao Y, Jing Y, Bo J, Li HH, Wang SH, Huang WR, et al. Adverse effects of PAD and VAD regimens in multiple myeloma patients. [Article in Chinese] Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010;18(4):1027\u201330."},{"issue":"1","key":"2955_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, H\u00e1jek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27\u201338.","journal-title":"Lancet Oncol"},{"issue":"7","key":"2955_CR18","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1200\/JCO.2013.52.3522","volume":"33","author":"KP Papadopoulos","year":"2015","unstructured":"Papadopoulos KP, Siegel DS, Vesole DH, Lee P, Rosen ST, Zojwalla N, et al. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and\/or refractory multiple myeloma. J Clin Oncol. 2015;33(7):732\u20139.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2955-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-016-2955-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2955-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T12:33:36Z","timestamp":1601210016000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2955-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,22]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2955"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2955-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,22]]},"article-number":"912"}}